Detail akcie VYNE Therap Rg online

Business Summary: VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vyne Therapeutics Inc revenues increased 6% to $440K. Net loss before extraordinary items decreased 22% to $21.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects operates in one segment loss decrease of 21% to $24.5M.